Clinical Trials Logo
  1. Home
  2. Chickenpox
  3. NCT05084508

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox Clinical Trial

Official title:
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life

Clinical Trial Summary

The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05084508
Study type Interventional
Source GlaxoSmithKline
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 3, 2022
Completion date July 5, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01887496 - Varicella-related Hospitalizations in Turkey N/A
Completed NCT02570126 - A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age. Phase 3
Completed NCT00326183 - Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Phase 4
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01817270 - Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Phase 4
Completed NCT01815073 - Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Phase 4
Active, not recruiting NCT01982409 - Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Phase 4
Completed NCT00921999 - Immune Response to Varicella-Zoster Vaccination and Infection N/A
Completed NCT00098046 - Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Phase 3
Completed NCT05732337 - Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device. N/A
Completed NCT01684072 - Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Phase 4
Completed NCT00156559 - MMR and Varicella Vaccine in Premature Infants Phase 4
Completed NCT04384016 - Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old Phase 4
Completed NCT00002358 - A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV Phase 3
Withdrawn NCT00001054 - The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children Phase 1
Completed NCT00000953 - Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients Phase 2
Completed NCT00001125 - Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox Phase 1
Completed NCT00002315 - A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems Phase 3